Most patients had pathologic infiltrating ductal carcinoma (94.9%), poorly differentiated (60.3%), T2 (68.0%), ER positive (74.8%), PR positive (68.6%) and HER2 negative (74.2%) disease. This evidence concerns the gene ESR1 and invasive ductal breast carcinoma.